Wyeth Aims For Two NME Launches A Year Under Retooled R&D Program
This article was originally published in The Pink Sheet Daily
Executive Summary
Changes to the R&D process include refocusing efforts on discovery of new molecular entities, with a reduced emphasis on line extensions. Only 23% of Wyeth’s portfolio is made up of line extensions versus 45% in 2001. Wyeth is also beginning to link scientist compensation to R&D goals.
You may also be interested in...
Wyeth Seeking "Novel" Partnerships For Oncology Pipeline
The company has 13 drugs in development for oncology indications, "far more" than it can afford to develop on its own. Wyeth is not interested in out-licensing or divesting the candidates but instead will pursue a "novel" development partnership.
Wyeth Seeking "Novel" Partnerships For Oncology Pipeline
The company has 13 drugs in development for oncology indications, "far more" than it can afford to develop on its own. Wyeth is not interested in out-licensing or divesting the candidates but instead will pursue a "novel" development partnership.
Effexor Follow-On Will Launch One Year Before XR Patent Expires, Wyeth Says
Advantages of DVS-233 over venlafaxine XR include improved safety profile and no dose titration requirement, Wyeth says. DVS-233 is also in Phase III studies for the treatment of vasomotor symptoms associated with menopause. Wyeth expects to file for approval in 2006.